Effect of cessation of zidovudine prophylaxis to reduce vertical transmission on maternal HIV disease progression and survival

Arlene D. Bardeguez, David E. Shapiro, Lynne M. Mofenson, Robert Coombs, Lisa M. Frenkel, Mary Glenn Fowler, Sharon Huang, Rhoda S. Sperling, Bethann Cunningham, Jorge Gandia, Robert Maupin, Carmen D. Zorrilla, Theodore Jones, Mary Jo O'Sullivan

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Zidovudine prophylaxis is recommended to reduce perinatal HIV-1 transmission, but there are limited data on long-term effects on women's health. Pediatrics AIDS Clinical Trials Group (PACTG) 288 was a prospective observational study among US women randomized to zidovudine or placebo in PACTG 076 that was designed to evaluate and compare postpartum clinical, immune, and viral parameters between randomized treatment arms. Forty-eight percent (226/474) of eligible women enrolled in the study (mean follow-up of 4.1 years). Progression and time to AIDS or death were similar in both groups, observed in 21 (19%) zidovudine group women and 29 (25%) placebo group women (RR = 0.73, 90% CI: 0.46-1.17). No significant differences in CD4+ lymphocyte count or HIV RNA levels were detected. Genotypic zidovudine resistance was detected in 10% of 156 women (9% of zidovudine group women and 11% of placebo group women). Based on our data, ZDV monotherapy could be considered as chemoprophylaxis to reduce perinatal HIV transmission for minimally symptomatic HIV-infected pregnant women with a low viral load and normal CD4+ cell count who do not want to receive highly active antiretroviral therapy because of concern about potential side effects or who wish to reduce fetal exposure to multiple drugs during pregnancy.

Original languageEnglish
Pages (from-to)170-181
Number of pages12
JournalJournal of Acquired Immune Deficiency Syndromes
Volume32
Issue number2
StatePublished - Feb 1 2003
Externally publishedYes

Fingerprint

Zidovudine
Disease Progression
Mothers
HIV
Survival
Acquired Immunodeficiency Syndrome
Placebos
CD4 Lymphocyte Count
Clinical Trials
Pediatrics
Highly Active Antiretroviral Therapy
Chemoprevention
Women's Health
Viral Load
Postpartum Period
Observational Studies
HIV-1
Pregnant Women
Prospective Studies
RNA

Keywords

  • Antiretroviral therapy
  • Disease progression
  • Genotypic resistance
  • PACTG 076 protocol
  • Perinatal transmission
  • Women
  • ZDV chemoprophylaxis

ASJC Scopus subject areas

  • Virology
  • Immunology

Cite this

Bardeguez, A. D., Shapiro, D. E., Mofenson, L. M., Coombs, R., Frenkel, L. M., Fowler, M. G., ... O'Sullivan, M. J. (2003). Effect of cessation of zidovudine prophylaxis to reduce vertical transmission on maternal HIV disease progression and survival. Journal of Acquired Immune Deficiency Syndromes, 32(2), 170-181.

Effect of cessation of zidovudine prophylaxis to reduce vertical transmission on maternal HIV disease progression and survival. / Bardeguez, Arlene D.; Shapiro, David E.; Mofenson, Lynne M.; Coombs, Robert; Frenkel, Lisa M.; Fowler, Mary Glenn; Huang, Sharon; Sperling, Rhoda S.; Cunningham, Bethann; Gandia, Jorge; Maupin, Robert; Zorrilla, Carmen D.; Jones, Theodore; O'Sullivan, Mary Jo.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 32, No. 2, 01.02.2003, p. 170-181.

Research output: Contribution to journalArticle

Bardeguez, AD, Shapiro, DE, Mofenson, LM, Coombs, R, Frenkel, LM, Fowler, MG, Huang, S, Sperling, RS, Cunningham, B, Gandia, J, Maupin, R, Zorrilla, CD, Jones, T & O'Sullivan, MJ 2003, 'Effect of cessation of zidovudine prophylaxis to reduce vertical transmission on maternal HIV disease progression and survival', Journal of Acquired Immune Deficiency Syndromes, vol. 32, no. 2, pp. 170-181.
Bardeguez, Arlene D. ; Shapiro, David E. ; Mofenson, Lynne M. ; Coombs, Robert ; Frenkel, Lisa M. ; Fowler, Mary Glenn ; Huang, Sharon ; Sperling, Rhoda S. ; Cunningham, Bethann ; Gandia, Jorge ; Maupin, Robert ; Zorrilla, Carmen D. ; Jones, Theodore ; O'Sullivan, Mary Jo. / Effect of cessation of zidovudine prophylaxis to reduce vertical transmission on maternal HIV disease progression and survival. In: Journal of Acquired Immune Deficiency Syndromes. 2003 ; Vol. 32, No. 2. pp. 170-181.
@article{7c30c8a5fde147c38d3a2dc1a75af652,
title = "Effect of cessation of zidovudine prophylaxis to reduce vertical transmission on maternal HIV disease progression and survival",
abstract = "Zidovudine prophylaxis is recommended to reduce perinatal HIV-1 transmission, but there are limited data on long-term effects on women's health. Pediatrics AIDS Clinical Trials Group (PACTG) 288 was a prospective observational study among US women randomized to zidovudine or placebo in PACTG 076 that was designed to evaluate and compare postpartum clinical, immune, and viral parameters between randomized treatment arms. Forty-eight percent (226/474) of eligible women enrolled in the study (mean follow-up of 4.1 years). Progression and time to AIDS or death were similar in both groups, observed in 21 (19{\%}) zidovudine group women and 29 (25{\%}) placebo group women (RR = 0.73, 90{\%} CI: 0.46-1.17). No significant differences in CD4+ lymphocyte count or HIV RNA levels were detected. Genotypic zidovudine resistance was detected in 10{\%} of 156 women (9{\%} of zidovudine group women and 11{\%} of placebo group women). Based on our data, ZDV monotherapy could be considered as chemoprophylaxis to reduce perinatal HIV transmission for minimally symptomatic HIV-infected pregnant women with a low viral load and normal CD4+ cell count who do not want to receive highly active antiretroviral therapy because of concern about potential side effects or who wish to reduce fetal exposure to multiple drugs during pregnancy.",
keywords = "Antiretroviral therapy, Disease progression, Genotypic resistance, PACTG 076 protocol, Perinatal transmission, Women, ZDV chemoprophylaxis",
author = "Bardeguez, {Arlene D.} and Shapiro, {David E.} and Mofenson, {Lynne M.} and Robert Coombs and Frenkel, {Lisa M.} and Fowler, {Mary Glenn} and Sharon Huang and Sperling, {Rhoda S.} and Bethann Cunningham and Jorge Gandia and Robert Maupin and Zorrilla, {Carmen D.} and Theodore Jones and O'Sullivan, {Mary Jo}",
year = "2003",
month = "2",
day = "1",
language = "English",
volume = "32",
pages = "170--181",
journal = "Journal of acquired immune deficiency syndromes (1999)",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins Ltd.",
number = "2",

}

TY - JOUR

T1 - Effect of cessation of zidovudine prophylaxis to reduce vertical transmission on maternal HIV disease progression and survival

AU - Bardeguez, Arlene D.

AU - Shapiro, David E.

AU - Mofenson, Lynne M.

AU - Coombs, Robert

AU - Frenkel, Lisa M.

AU - Fowler, Mary Glenn

AU - Huang, Sharon

AU - Sperling, Rhoda S.

AU - Cunningham, Bethann

AU - Gandia, Jorge

AU - Maupin, Robert

AU - Zorrilla, Carmen D.

AU - Jones, Theodore

AU - O'Sullivan, Mary Jo

PY - 2003/2/1

Y1 - 2003/2/1

N2 - Zidovudine prophylaxis is recommended to reduce perinatal HIV-1 transmission, but there are limited data on long-term effects on women's health. Pediatrics AIDS Clinical Trials Group (PACTG) 288 was a prospective observational study among US women randomized to zidovudine or placebo in PACTG 076 that was designed to evaluate and compare postpartum clinical, immune, and viral parameters between randomized treatment arms. Forty-eight percent (226/474) of eligible women enrolled in the study (mean follow-up of 4.1 years). Progression and time to AIDS or death were similar in both groups, observed in 21 (19%) zidovudine group women and 29 (25%) placebo group women (RR = 0.73, 90% CI: 0.46-1.17). No significant differences in CD4+ lymphocyte count or HIV RNA levels were detected. Genotypic zidovudine resistance was detected in 10% of 156 women (9% of zidovudine group women and 11% of placebo group women). Based on our data, ZDV monotherapy could be considered as chemoprophylaxis to reduce perinatal HIV transmission for minimally symptomatic HIV-infected pregnant women with a low viral load and normal CD4+ cell count who do not want to receive highly active antiretroviral therapy because of concern about potential side effects or who wish to reduce fetal exposure to multiple drugs during pregnancy.

AB - Zidovudine prophylaxis is recommended to reduce perinatal HIV-1 transmission, but there are limited data on long-term effects on women's health. Pediatrics AIDS Clinical Trials Group (PACTG) 288 was a prospective observational study among US women randomized to zidovudine or placebo in PACTG 076 that was designed to evaluate and compare postpartum clinical, immune, and viral parameters between randomized treatment arms. Forty-eight percent (226/474) of eligible women enrolled in the study (mean follow-up of 4.1 years). Progression and time to AIDS or death were similar in both groups, observed in 21 (19%) zidovudine group women and 29 (25%) placebo group women (RR = 0.73, 90% CI: 0.46-1.17). No significant differences in CD4+ lymphocyte count or HIV RNA levels were detected. Genotypic zidovudine resistance was detected in 10% of 156 women (9% of zidovudine group women and 11% of placebo group women). Based on our data, ZDV monotherapy could be considered as chemoprophylaxis to reduce perinatal HIV transmission for minimally symptomatic HIV-infected pregnant women with a low viral load and normal CD4+ cell count who do not want to receive highly active antiretroviral therapy because of concern about potential side effects or who wish to reduce fetal exposure to multiple drugs during pregnancy.

KW - Antiretroviral therapy

KW - Disease progression

KW - Genotypic resistance

KW - PACTG 076 protocol

KW - Perinatal transmission

KW - Women

KW - ZDV chemoprophylaxis

UR - http://www.scopus.com/inward/record.url?scp=0037321530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037321530&partnerID=8YFLogxK

M3 - Article

C2 - 12571527

AN - SCOPUS:0037321530

VL - 32

SP - 170

EP - 181

JO - Journal of acquired immune deficiency syndromes (1999)

JF - Journal of acquired immune deficiency syndromes (1999)

SN - 1525-4135

IS - 2

ER -